secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001829126-26-003165
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled
--------------------------------------------------------------------------------

- Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.
- NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.
- NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.
- PIPE financing anchored by $10M commitment from Cinctive Capital Management.
- Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/0001829126-26-003165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-003165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer